| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 633 |
| 1 | METHYLPREDNISOLONE | 473 |
| 2 | ACETAMINOPHEN | 444 |
| 3 | PREDNISONE | 424 |
| 4 | PAIN RELIEVER | 386 |
| 5 | ACETAMINOPHEN 500MG | 385 |
| 6 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 385 |
| 7 | METHOTREXATE SODIUM | 382 |
| 8 | INFLIXIMAB | 312 |
| 9 | INFLIXIMAB-DYYB | 311 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | USTEKINUMAB-STBA | 45 | 0.1213 |
| 1 | INFLIXIMAB-DYYB | 311 | 0.0902 |
| 2 | BEVACIZUMAB-ADCD | 7 | 0.0345 |
| 3 | MARSTACIMAB-HNCQ | 3 | 0.0291 |
| 4 | CARBOPROST TROMETHAMINE | 15 | 0.0204 |
| 5 | ELRANATAMAB-BCMM | 23 | 0.0199 |
| 6 | ASIAN GINSENG | 6 | 0.0142 |
| 7 | SPARSENTAN | 95 | 0.0140 |
| 8 | TRICLOSAN | 7 | 0.0121 |
| 9 | NAXITAMAB | 3 | 0.0120 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 906 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 679 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 535 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 429 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 286 |
| 5 | Platinum-based Drug [EPC] | 245 |
| 6 | Kinase Inhibitor [EPC] | 224 |
| 7 | Alkylating Drug [EPC] | 217 |
| 8 | Interleukin-12 Antagonist [EPC] | 214 |
| 9 | Interleukin-23 Antagonist [EPC] | 214 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Polyene Antimicrobial [EPC] | 2 | 0.0049 |
| 1 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 5 | 0.0046 |
| 2 | Interferon gamma Blocker [EPC] | 1 | 0.0042 |
| 3 | Tetracycline-class Antibacterial [EPC] | 31 | 0.0039 |
| 4 | Oxytocic [EPC] | 12 | 0.0039 |
| 5 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 15 | 0.0037 |
| 6 | Serotonin-4 Receptor Agonist [EPC] | 2 | 0.0030 |
| 7 | Echinocandin Antifungal [EPC] | 24 | 0.0029 |
| 8 | Progestin Antagonist [EPC] | 12 | 0.0025 |
| 9 | Oxazolidinone Antibacterial [EPC] | 76 | 0.0025 |